The matrix metalloprotease matrilysin is expressed in premalignant polyps and plays a key role in local invasion during the progression of digestive tumors. In the present work, we investigated the possible relationships between the activity of the mouse and human matrilysin promoters (Mp), endogenous matrilysin protein expression, and two early oncogenetic defects frequently observed in human colonic cancers, namely activation of the src oncogene and impairment of the Wnt/APC/β-catenin pathway. Using transient transfection assays, we report here that src signaling and the HMG-box transcription factor LEF-1 act synergistically with the proximal (-61 to -67) AP-1 binding site to transactivate the Mp in premalignant and tumorigenic kidney and colonic epithelial cells, through β-catenin-and axin-independent signaling pathways. This synergism involves the -109 and -194 Tcf/LEF-1 binding sites in the Mp and a physical interaction between LEF-1 and c-Jun. Furthermore, src coordinates accumulation of the c-Jun factor and matrilysin transcripts. Conversely, the c-Jun dominant negative mutant TAM67 and the src tyrosine kinase inhibitor M475271 impaired src-induced Mp activation, matrilysin protein accumulation, and invasion of type I collagen gels. This mechanism may thereby contribute to cellular invasion during the early-stage adenoma/adenocarcinoma conversion and the metastatic process of digestive tumors.
cells and their stromal environment, including the degradation of the basement membrane components and extracellular matrix within the tumor stroma. Matrix metalloproteases (MMPs) belong to a family of structurally related proteases implicated in cell growth, matrix remodeling during tissue morphogenesis, inflammation, wound healing, angiogenesis, and metastasis (1, 2) . There is a general agreement that MMPs play a major role in the migration of transformed cells through the extracellular matrix. Several MMPs degrade collagens, the most abundant components of the extracellular matrix and tumor stroma (1) . Matrix metalloprotease matrilysin (MMP-7, or EC 3.4.24.23), which belongs to the stromelysin subfamily, cleaves a wide spectrum of extracellular matrix proteins, such as nonfibrillar collagens, fibronectin, entactin, laminin, elastin, and tenascin (2) . Matrilysin expression has been detected in normal tissues, including the glomerular mesangium and normal kidney cells and is induced in a majority of human colonic tumor cell lines (3, 4) . Contrary to the other MMPs, such as stromelysin-3, which are secreted by the surrounding stromal cells in breast and colon cancers (5) , matrilysin is predominantly expressed in differentiated epithelial cancer cells of glandular tissues (2) .
Overexpression of matrilysin has been reported in several human solid tumors of breast, prostate, lung, gastrointestinal tract (2) , and 90% of adenomas from FAP familial adenomatous polyposis patients (6, 7) . The increased expression of matrilysin in premalignant polyps strongly suggests a priming role for this MMP in early stages of tumor progression, before the onset of the invasive phenotype in primary tumors (8, 9) . Accordingly, invalidation of the MMP-7 gene in the multiple intestinal neoplasia (Min) mouse resulted in a 60% reduction in mean tumor multiplicity, suggesting that matrilysin contributes to tumor growth and remodeling of the intestinal mucosa in a subset of colonic adenomas (6) . Furthermore, matrilysin overexpression at the mRNA and protein levels is associated with tumor progression in colorectal carcinomas (8) (9) (10) , suggesting its persistent and critical role during later stages of tumor cell invasiveness, leading to the formation of distant metastases in vital organs. Most interestingly, a nonconventional role for matrilysin in the release of signaling effectors has been recently demonstrated, including tumor necrosis factor (TNF)-α, Fas ligand, as well as β4-integrin and Ecadherin, two key regulators in the metastatic process during colon cancer progression (11) (12) (13) .
The mechanisms underlying the transcriptional regulation of the matrilysin promoter gene (Mp) are still poorly understood. Recent studies have shown that oncogenic β-catenin up-regulates the matrilysin promoter (7, 14) , suggesting that the molecular components of the Wnt/APC/LEF-1 signaling pathways are implicated in the aberrant expression of matrilysin in colon cancer. Molecular and functional alterations in the elements of the Wnt/APC/β-catenin play a critical role in the emergence of FAP and the development of a large proportion of human sporadic colonic tumors (15, 16) . Early oncogenetic defects are frequently associated with inactivation of the tumor suppressor genes APC (adenomatous polyposis coli), AXIN, TCF-4, SMAD2, and SMAD4; inactivation of TGFβ-type II receptors; and activating mutations of the protooncogenes ras, src, met, and CTNNB1 encoding β-catenins (15, (17) (18) (19) (20) . Several other oncogenic pathways, epigenetic factors, and downstream signaling elements are also implicated in the development of human colorectal cancers. The oncoprotein src regulates a variety of cellular functions, including proliferation, survival, adhesion, migration, and tumor invasion (21) .
c-src was the first identified oncogene acting as a nonreceptor protein tyrosine kinase (22) . Activation of the src oncogene is frequently associated with the emergence of premalignant colonic adenomatous lesions. Accordingly, src activity is increased five-to eightfold in the majority of human colonic tumors (23, 24) and correlates with elevated secretion of MMP-2 and expression of MMP-9 (25, 26) . Src activation triggers multiple interdependent signaling cascades linked to transcriptional regulations mediated by DNA binding of signal transducer and activator of transcription 3 (STAT3) and activator protein-1 (AP-1). The transcription factor AP-1 consists of either a Jun-Jun homodimer or a more stable Jun-Fos heterodimer and can be activated by phorbol ester tumor promoters such as 12-O-tetradecanoylphorbol-β-acetate (TPA), through the protein kinase C (PKC) pathway. The promoter region of the human matrilysin gene harbors several regulatory regions (27) containing binding sites for the transcription factors Tcf (positions -194 to -188 and -109 to -103), Ets (-168 to -165, -144 to -141, and -55 to -52), and AP-1 (-67 to -61). Depending on the neoplastic status, the AP-1 transcription factor transduces mitogenic-and cellular transformation-associated signals from activated growth factor receptors and oncogenes, through PKC, mitogen-activated protein kinases p42/p44 (MAPK), phosphatidylinositol 3-kinase (PI3-K), and stress-activated protein kinases SAPK and JNK (28) (29) (30) . Accordingly, we have presented evidence that both PI3-K-α and -γ play a key role in tumor invasion and cell survival (31, 32) .
We therefore speculate that the src oncogene may contribute to the regulation of matrilysin expression through the Fos and Jun transcription factors acting at the AP-1 binding site of the Mp. In the present work, we analyze the functional activity of the human and mouse Mp in response to src activation, in concert with other putative transactivators acting on its Tcf and Ets binding sites, that is, LEF-1/β-catenin and the PEA3 member of the Ets transcription factors, respectively. Using transiently transfected kidney and colonic epithelial cells MDCKts.src and HCT8/S11 (33, 34) , we show that the transcriptional activation of the Mp by src is remarkably enhanced by LEF-1 through a Wnt/APC/β-catenin-independent signaling pathway. To more precisely define the role of oncogenic src and AP-1 transactivation in matrilysin promoter activity, we decided to characterize the binding properties of oligonucleotides containing the AP-1 consensus sequence by using gel retardation assays and nuclear extracts prepared from HCT8/S11 cells transiently transfected by src. By functional and mutational analyses of the Mp, constitutive expression of the c-Jun dominant negative mutant TAM67 in stably transfected MDCKts.src-TAM67 cells, and GST-LEF-1 pull-down assay, we report here that the proximal AP-1 (-61 to -67) and Tcf/LEF-1 (-109 and -194) binding sites play a critical role in the activation of the matrilysin promoter and cellular invasion by src, via a cooperative interaction between the AP-1 component c-Jun and LEF-1. We have also extended these studies to determine the implication of the PKC/MAPK and PI3-K pathways in these transcriptional and cellular responses.
MATERIALS AND METHODS

Cell culture
Premalignant MDCK canine kidney epithelial cells, MDCKts.src cancer cells transformed by a temperature-sensitive mutant of the v-src oncogene (33) , and the HT-29 human colorectal cancer cell line were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Cergy Pontoise, France) supplemented with 10% fetal bovine serum (FBS) and antibiotics (Roche Molecular Biochemicals, Meylan, France). MDCKts.src cells display an invasive phenotype at the permissive temperature of 35°C for src activation and are not invasive at the restrictive temperature of 40°C. The PC/AA/C1 cell line established from a colonic adenoma in a patient with familial adenomatous polyposis was designated as the parental PC cell line throughout this study. After transfer of the activated c-src oncogene, PCmsrc cells become tumorigenic and susceptible to invasiveness upon addition of HGF (35) . PC and PCmsrc cells were cultured in DMEM supplemented with 20% FBS and antibiotics, as previously described (35) . The human colorectal cell line HCT8/S11 was cultured in RPMI 1640 (Invitrogen) containing 10% FBS (34) .
Plasmids and reagents
The src expression vector pSGT-srcY527F and its corresponding control empty vector pSGT were provided by Dr. Serge Roche (CNRS UPR-1086 CRBM, Montpellier, France). The -2.7 kb mouse Mp (pGL2Bas2.7mMat), the wild-type and mutated constructs of the human Mp reporter plasmids (-296HMAT-Luc), the pCAN-PEA3, and the pcineo-LEF-1 expression vectors were described elsewhere (3, 14) . The pGEX-LEF-1 vector was a gift from Dr. A. Hecht (Max-Planck Institute, Freiburg, Germany). The TAM67 vector, encoding a c-jun protein lacking the transactivation domain (amino acids 3-122) was provided by Dr. Michael J. Birrer (National Institutes of Health, Bethesda, MD), the ∆N89β-catenin vector encoding a truncated stable form of β-catenin was a gift from Dr. Paul Polakis (GENENTEC, South San Francisco, CA), the wildtype axin vector was from Dr. Trevor Dale (Institute for Cancer Research, London), and the pMLZ-TopFlash and pMLZ-FopFlash vectors containing three wild-type and three mutated repeats of a Tcf/β-catenin DNA binding sequence, respectively, were provided by Dr. Laurent Debussche (Aventis Pharma, France). The src inhibitor M475271 was provided by Dr. Anderson Ryan (AstraZenaca, Macclesfield, UK). In ELISAs with recombinant enzymes assaying tyrosine phosphorylation of peptide substrates, the new anilinoquinazoline derivative M475271 was shown to be a potent and selective inhibitor of src kinase activity (Dr. Anderson Ryan, personal communication). IC 50 values were determined as follows: src (25 nM), yes (10 nM), lck (0.2 µM), csk (7.6 µM), VEGFR2 (0.5 µM), EGFR (0.6 µM), and FGFR1 (∼20 µM). The PP1 src kinase inhibitor was obtained from BIOMOL Research Laboratories (TEBU, Le Perray en Yvelines, France). The PKC activator phorbol 12-myristate 13-acetate (TPA) and the PI3-K inhibitor LY294002 were from Sigma (Saint-Quentin Fallavier, France). The pharmacological inhibitors of the MAPK p42/44 (PD98059) and PKC (Gö6976) were from Calbiochem (Meudon, France).
Transient transfections and luciferase reporter gene assays
Kidney and colonic epithelial cells were seeded in six-well plates at a density of 75,000-200,000 cells/well. After overnight adhesion, cells were transfected with 1 µg of the MMP-7 promoter reporter constructs (Mp), using the LipofectAMINE Reagent (Invitrogen). Where indicated, the transfection mixture was combined with 0.25 µg of plasmid vectors encoding either src, PEA3, ∆N89β-catenin, LEF-1, axin, or TAM67, and 1 ng of the pSV40-RL Renilla luciferase vector as internal control (Promega, Charbonnières, France) (14) . Before assaying for luciferase activity, MDCK and HCT8/S11 cells were cultured for 18 h after transfection and were treated for 6 h with the vehicle buffer alone or supplemented with the pharmacological inhibitors of the PKC/MAPK and PI3-K pathways, namely Gö6976 (1 µM)/PD98059 (50 µM) and LY294002 (10 µM), respectively. MDCKts.src cells were cultured for 18 h at 40°C and for an additional 6-h period at 40°C or 35°C after transfection, in order to induce the activation of the ts.src oncogene. Other pharmacological inhibitors and control vehicle were added 30 min before the temperature shift. Kidney and colonic cells were then washed with cold phosphatebuffered saline (PBS) and scraped into the luciferase lysis buffer. Luciferase assays were performed using the Dual Luciferase Reporter Assay System Kit (Promega). Luciferase activities were normalized according to the Renilla luciferase activity. Values shown are mean ±SE of at least three independent experiments, each performed in triplicate.
Stable transfections, immunoblotting, and ELISA immunodetection
For expression of the dominant negative form of c-Jun (TAM67), MDCKts.src cells were plated for 24 h on 60-mm-diameter dishes and stably transfected by lipofection (LipofectAMINE reagent), according to the manufacturer's instructions. Cells were transfected with 4 µg of the pCMV-TAM67 plasmid and 0.4 µg of the pcDNA3 vector carrying the neomycine resistance gene. After 24 h, cultures were split into 100-mm-diameter dishes and selected for 10 days in 1 mg/ml G418 (Invitrogen). Resistant colonies were ring-cloned as individual clones or pooled. Expression of the transgene was determined by Western blotting. In brief, cultured cells were lysed in cold lysis buffer, and proteins (200 µg) were resolved on a 15% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred to PVDF membranes (Amersham-Pharmacia Biotech, Orsay, France). Membranes were blocked overnight at 4°C in 0.1% PBS-Tween containing 5% dried skim milk. The blots were probed for 1 h at room temperature with the rabbit polyclonal antibody Ab-1 against the conserved DNA binding domain of c-jun (Oncogene Research, Meudon, France).
For matrilysin immunoblot analysis, human colonic cancer cells HT-29 were grown to confluence and incubated for 24 and 48 h in the presence or absence of the src inhibitors M475271 (10 −6 M or 10 −5 M) and PP1 (10 −5 M), and then cultured under the same conditions for an additional 24 h at low serum concentration (0.1% FBS). Each conditioned medium was collected, and 25 µg of the corresponding lyophilized proteins were resolved on a 15% SDS-PAGE gel and transferred to PVDF membranes. Membranes were blocked in TBS-Tween containing 0.1-5% dried skim milk and probed overnight at 4°C with a 1:6 dilution of monoclonal rat anti-human matrilysin hybridoma supernatant in TBS-Tween 0.1%, as described previously (14) . Membranes were then washed and probed with a peroxydase-conjugated goat anti-rat antibody (TEBU; Santa Cruz Biotechnology, Santa Cruz, CA). Matrilysin ELISA tests were carried out on the conditioned media collected from PP1-treated HT-29 cells (1:10 
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from MDCKts.src cells cultured at 40°C or 35°C and pSGT-and pSGT-src-Y527F-transfected HCT8/S11 cells, according to the protocol described by Andrews and Faller (36) . Oligonucleotides used for EMSA were wt AP-1 (5′-AGCTTCAAATGAGTCAACTATTG-3′) and mut AP-1 (5′-AGCTTCAAACGAGTGACCTATTG-3′). Probes were made by annealing complementary oligonucleotides. Equimolar amounts of each oligonucleotide were incubated for 10 min at 95°C, 10 min at 60°C, and 10 min at 40°C, and the probe was labeled by filling in with the Klenow enzyme (Invitrogen) in the presence of [α-32 P]dGTP for 30 min. EMSA was performed by incubating 5 µg of nuclear extracts for 15 min with 2 µg of poly(dI-dC) in 2 mM DTT and 2.5 mM MgCl 2 , and adding to the mix 2 ng of 32 P-labeled probe in 20 mM Tris-HCl buffer containing 6% glycerol. When unlabeled oligonucleotides were added, a 50-fold excess was included in the binding reaction. Binding was then allowed to proceed for 30 min at room temperature before analysis on a 6% acrylamide/0.25× TBE gel run at 25 mA. After electrophoresis, the gel was dried under vacuum, and Kodak (Rochester, NY) films were exposed for 4 h at 4°C.
Collagen invasion assay
For invasion of collagen gels by MDCKts.src cells, petri dishes were filled with 1.35 ml of neutralized type I collagen (Upstate Biotechnology, Lake Placid, NY) and incubated overnight at 37°C to allow gelling. Cells were harvested using Moscona buffer and trypsin/EDTA, and seeded on top of the collagen gels. Cultures were incubated for 24 h at the indicated temperature in the presence or absence of appropriate inhibitors of the signaling pathways downstream oncogenic src. The depth of cell migration inside the gels was measured using an inverted microscope (37) . Invasive and superficial cells were counted in 12 fields of 0.157 mm 2 . The invasion index is the percentage of cells invading the gel over the total number of cells.
Glutathione S-transferase-LEF-1 (GST-LEF-1) pull-down assay
Recombinant c-Jun cDNA in pSG5 was transcribed and translated in rabbit reticulocyte lysates in the presence of 35 S-methionine. Then, 35 S-labeled c-Jun was incubated with the GST-LEF-1 fusion protein for 2 h at 4°C in the NTEN buffer containing 20 mM Tris/HCl (pH 8), 1 mM EDTA, Nonidet P40, and 100 mM NaCl. The beads were washed twice with NTEN and with NTEN buffer containing 250 mM NaCl. Samples were analyzed by SDS-PAGE (10% [w/v] gel) after elution of the bound proteins by SDS-sample loading buffer. The amount of 35 S-labeled cJun bound to the GST-LEF1 fusion protein was detected by autoradiography.
RNA isolation and reverse transcriptase-polymerase chain reaction (RT-PCR) amplification
Total RNA was extracted from human colonic cells PC and PCmsrc, using the Trizol reagent (Invitrogen), according to the manufacturer's instructions. RT-PCR analyses were performed with the SuperScript One-Step RT-PCR kit (Invitrogen). In brief, 1 µg of total RNA was reverse transcribed and a 365-bp fragment of the human matrilysin cDNA was amplified using the specific primers 5′-AGATGTGGAGTGCCAGATGT-3′ and 5′-TAGACTGCTACCATCCGTCC-3′. A GAPDH amplification was also performed as an internal control using the following primers: 5′-ATCACCATCTTCCAGGAGCG-3′ and 5′-CCTGCTTCACCACCTTCTTG-3′. Reverse transcription was performed for 30 min at 50°C and PCR amplification during 35 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min 30 and extension at 72°C for 1 min. PCR products were resolved on a 2% agarose gel stained with ethidium bromide.
RESULTS AND DISCUSSION
Src induces matrilysin promoter activity
To determine whether src activates the Mp, we used two luciferase reporter constructs, one bearing the human matrilysin promoter fragment from -296 to +35 (-296HMAT-Luc) and the other one bearing the -2.7 kb mouse promoter fragment (pGL2-MMP7). Because matrilysin expression is restricted to epithelial cells, transient transfections using Mp-luciferase gene constructs were performed in epithelial cell lines at different stages of the neoplastic progression, including parental MDCK and v-src-transformed MDCKts.src kidney epithelial cells and HCT8/S11 cells established from a human colonic adenocarcinoma. MDCKts.src cells display an invasive phenotype at the permissive temperature of 35°C for v-src activation and are not spontaneously invasive at the restrictive temperature of 40°C (33) .
As shown in Figure 1A and 1B, activation of the ts.src in MDCKts.src cells by shift to the permissive temperature, 35°C, for 6 h clearly up-regulated the transcription of the human and mouse matrilysin promoters 8.3-and 5-fold, respectively. Accordingly, transient transfection of the parental MDCK cells and HCT8/S11 cells with 0.25 µg of pSGT-srcY572F encoding the src oncogene leads to similar activation of the human and mouse MMP-7 promoters (3.5-to 6-fold) as compared with the empty vector (pSGT). This stimulation was much higher than the known stimulatory effect of TPA on the MMP-7 promoter (7, 27) , because this PKC activator stimulated 1.8-to 3.4-fold the human and mouse Mp in MDCK and HCT8/S11 cells, as shown in Figure 1 .
Implication of the PKC/MAPK and PI3-K signaling pathways in the activation of the MMP-7 promoter by src
Recent data indicate that src signaling involves a complex array of downstream pathways, including the PI3-K and PKC/MAPK cascades comprising the p42/p44 and p38 serine-threonine kinases (31, 38, 39) . We therefore asked whether the inactivation of these pathways might interfere with the transactivation of the human Mp by src. Treatment of HCT8/S11 cells with the specific PI3-K inhibitor LY294002 and the p42/p44 MAPK inhibitor PD98059 reduced by 50-80% the activity of the human Mp induced by src (Fig. 2) . Most interestingly, simultaneous addition of the PI3-K and MEK1 inhibitors fully reversed the activity of the human Mp induced by src in HCT8/S11 cells, suggesting that parallel and convergent signaling pathways are initiated from the membrane-bound src oncogene toward the regulatory sequences in the Mp promoter. In contrast, activation of the mouse Mp by src was insensitive to the p38 MAPK inhibitor SB203580 in the MDCKts.src cell line incubated at the permissive temperature, 35°C, for src activation (data not shown).
In agreement with the data presented in Figure 1 , the PKCα and -β inhibitor Gö6976 induced a partial reversion of human Mp activation induced by src in HCT8/S11 cells (Fig. 2) . Similar results were obtained using the mouse Mp-luciferase reporter gene expressed in v-srctransformed MDCKts.src cells incubated in the presence or absence of the pharmacological inhibitors of PKC, p42/p44 MAPK, and PI3-K (data not shown). These inhibitors also abolished cellular invasion induced by v-src in MDCKts.src cells, suggesting a possible contribution of matrilysin in the invasive phenotype determined by oncogenic src (Fig. 3) . Thus, PKC may act upstream of the Raf-MEK1/p42/p44 MAPK cascade. The transforming functions of PKCα have been established in human colorectal cancer cells, Caco-2, stably transfected by the ras oncogene and the src activator polyoma middle T (40, 41) . Accordingly, expression of an activated form of PKCα in HT29 cancer cells induced the acquisition of a scattered phenotype and invasion of chick embryo heart fragments (42) .
Synergistic interactions between src and LEF-1 in the transcriptional activation of the matrilysin promoter
In human kidney epithelial cells HEK293, the matrilysin promoter was shown to be activated by PEA3, a member of the Ets transcription factors superfamily, and by the bipartite LEF-1/β-catenin complex in HT-29 and HCT116 colon cancer cell lines displaying a low level of endogenous β-catenin/Tcf complexes (3). Using cotransfection assays, we demonstrate here that both PEA3 and the stable transforming mutant of β-catenin, ∆N89β-cat (43), do not individually up-regulate the Mp, and do not act synergistically with src in transiently transfected colonic HCT8/S11 cells (Fig. 4A) . Because the activation of the Mp is dependent on the level of endogenous β-catenin (3), we next examined the status of the Wnt/APC/β-catenin signaling cascade in HCT8/S11 cells. To test this, we used the TopFlash plasmid containing a luciferase reporter gene positioned downstream from three lymphoid enhancer factor binding sites (44) . As shown in Figure 4B (right), high activity of the TopFlash reporter was detected, in comparison with the FopFlash construct in which the LEF/β-catenin binding sites are mutated. Thus, we conclude that the Wnt/β-catenin/LEF signaling pathway is already activated in HCT8/S11 cells (Fig. 4B, right) . Because PEA3 is up-regulated in response to Wnt signaling and APC mutations in human colorectal cancer cells (45) , one can postulate that HCT8/S11 cells are consequently insensitive to addition of exogenous PEA3 regarding the activity of the Mp (Fig. 4A ). This would be consistent with the previous observation that all human colon tumor cell lines examined express PEA3 (14) .
The transcriptional activity of β-catenin in the canonical Wnt/APC/β-catenin pathway also requires its association with LEF-1, a member of the lymphoid enhancer factor/T cell factor (LEF/Tcf) transcription factor family. LEF-1 binds the Tcf sites of the Mp and was previously described alternatively as a transcriptional repressor and adaptator for β-catenin binding to regulatory sequences, leading to transcriptional activation of target genes involved in colon cancer progression, such as myc, cyclin D1, and cyclooxygenase-2 (46) . Most interestingly, we found that LEF-1 alone increased Mp activity about 2.5-fold in HCT8/S11 cells, whereas coexpression of LEF-1 and oncogenic src enhances matrilysin transcription up to 16.7-fold, demonstrating a remarkable synergism between these two transcriptional mechanisms (Fig. 4A) .
We next examined whether the transcriptional effects of LEF-1 alone or combined with src were associated with its capacity to bind a residual fraction of free β-catenin in HCT8/S11 cells. We therefore cotransfected HCT8/S11 cells with axin, a negative regulator of the Wnt/APC/β-catenin signaling pathway implicated in colon cancer (47) (48) (49) (50) . The scaffold protein axin binds APC and GSK3-β to form a complex that interacts with β-catenin and promotes its ubiquitination and degradation by the proteasome in the absence of extracellular signals monitored by the Wnt proteins, a large family of secreted molecules associated with the extracellular matrix. However, axin overexpression had no effect on the basal Mp activity and did not affect src or LEF-1 transactivation of the Mp (Fig. 4B, left) , although cotransfection of axin with the TopFlash/FopFlash reporter plasmids inhibited by 60% the β-catenin-dependent transcription in HCT8/S11 cells (Fig. 4B, right) .
Taken together, our data strongly suggest that LEF-1 is not acting on the Mp through the canonical Wnt/APC/β-catenin pathway. Accordingly, a mutant form of LEF-1 lacking the β-catenin interaction domain was shown to transactivate the T cell receptor (TCR)α enhancer, indicating a β-catenin-independent transactivation potential for LEF-1 (51). The TCRα enhancer activity requires the binding of LEF-1 to the coactivator ALY, which in turn recruits another nuclear factor, AML-1. The HMG1-like high mobility group domain of LEF-1, which mediates DNA binding, introduces a sharp bend in the DNA, which allows cofactors bound at the vicinity of LEF-1 sites to assemble into a multimolecular transcriptional complex. Thus, in the nucleus, LEF-1/Tcf proteins cooperate alternatively with other DNA-bound factors in a contextdependent manner, demonstrating the involvement of the architectural factors LEF/Tcf in the integration of upstream signals at the DNA level.
Src-induced activation of the human matrilysin promoter requires the activation of AP-1 signaling and a cooperative interaction between c-Jun and LEF-1 transcription factors.
Two Tcf binding sites, three binding sites for the Ets transcription factors and one AP-1 motif between positions -67 and -61 were already described in the promoter of the human matrilysin gene (27) . To determine which sites are targeted by oncogenic src, HCT8/S11 cells were transfected with wild-type or mutated constructs of the -296bp human Mp cloned upstream the luciferase gene. As shown in Figure 4C , two inactivating point mutations in the AP-1 binding site (5′-CAAACGAGTGACCTATTTCCAC-3′) abolished src responsiveness. In contrast, inactivating mutations within the Ets (-144 mEts) and Tcf elements (-109/-194 mTcf) did not interfere with Mp activation by src in HCT8/S11 cells.
Because the AP-1 site plays a critical role in the regulation of the Mp, we further analyzed by gel retardation assays the functional activity of the AP-1 response element in src-transformed HCT8/S11 colonic cells and MDCKts.src kidney cells. To verify AP-1 binding, we used 32 Plabeled oligonucleotides corresponding to the wild-type or mutated AP-1 motif. The mutated AP-1 oligonucleotide probe was generated by introducing the two inactivating point mutations shown to abrogate the transactivation of the Mp by src (Fig. 4C) . Both probes were incubated with nuclear extracts prepared from HCT8/S11 cells transiently transfected by src and MDCKts.src grown at the permissive and nonpermissive temperatures for v-src activation. The basal level of DNA binding activity detected in the extracts of both HCT8/S11 and MDCKts.src cells (lane 2) (Fig. 5A ) was remarkably enhanced after overexpression of activated src (lane 3). As competitor, a 50-fold excess of the corresponding unlabeled double-stranded oligonucleotide was added to the binding reaction and abolished binding of nuclear factors to the wt AP-1 probe (lane 4) (Fig. 5A) . As expected, binding was unaffected by the addition of an excess of unlabeled mutated probe (data not shown). Moreover, no complexes were formed in the presence of the mutated AP-1 probe (mut AP-1, lanes 1-3) , demonstrating the specificity of src-induced DNA binding of the nuclear transcription factors at the AP-1 site of the Mp.
Because c-Jun is a prominent component of the AP-1 transcription complexes, we next examined the expression profile of the endogenous c-Jun protein by Western-blot in the MDCKts.src and PCmsrc cell lines stably transfected by the src oncogene. We show here that src up-regulates cJun expression in both MDCKts.src and PCmsrc cells (Fig. 5B) . Thus, the transcriptional response of the Mp to src activation seems to occur through a dual mechanism involving an increased stability of the DNA-bound AP-1 complex (Fig. 5A ) and a concomitant elevation of cJun levels. These results are in agreement with a recent study demonstrating that accumulation of the matrilysin transcripts is directly correlated with c-Jun mRNA levels in human solid tumors (52) . Consistent with this observation, transcriptional activation of the Mp by src also resulted in a twofold increase in the matrilysin transcripts levels in PCmsrc cells, as compared with the parental PC cells (Fig. 5C) . Transformation of the premalignant colonic epithelial PC cells by the c-src oncogene induced the tumorigenic potential in their PCmsrc counterparts and invasiveness in response to hepatocyte growth factor (35) . Activation of the src oncogene has been reported to be frequently associated with premalignant colon adenomatous mucosa. Two steps of src activation take place during colonic carcinogenesis, one in the polyps and primary tumors and a second greater increase in liver metastasis (53) . Thus, the synergistic cooperation between the AP-1 and LEF-1 transcription factors in the activation of the Mp gene reporter is directly related to the consequent elevation of the endogenous c-Jun protein and matrilysin messengers levels in src-transformed cells.
Therefore, we next examined the relative contribution of the LEF/TCF binding sites (-109 and -194) in the AP-1/LEF-1 synergism at the Mp in src-transformed cells. Using HCT8/S11 cells transiently transfected by the src oncogene and the wild-type (wt), single mutant (-109 Tcf mut, -194 Tcf mut) and double mutant matrilysin promoters (-109/-194 Tcf mut), we found that the LEF-1/src synergism on the Mp activity is abrogated when both Tcf sites are inactivated in the -109/-194 Tcf mut promoter (Fig. 5D) . In this case, we observed no significant effect of LEF-1, using the double mutant -109/-194 Tcf promoter. When we mutated only one Tcf response element in the -109 or -194 Tcf mut, the Mp was still activated by src or LEF-1 alone, but the synergism between src and LEF-1 was lost, indicating that both Tcf sites are able to work with the AP-1 response element during the activation of the Mp by src and LEF-1. Given the proximity of the AP-1 and LEF-1 binding sites in the Mp, and the ability of these transcription factors to promote a synergistic activation of the matrilysin gene, we predicted a potential mechanism by which the AP-1 complex and LEF-1 might interact together at these two adjacent DNA motifs. In order to explore this hypothesis, we used the immobilized GST-LEF-1 to assess its ability to interact with in vitro-translated 35 S-methionine-labeled c-Jun. In this context, we demonstrated that indeed LEF-1 interacts physically with c-Jun (Fig. 5E ).
The AP-1 component c-Jun is involved in src-induced activation of the Mp and cellular invasion.
To more precisely define the role of the AP-1 complex in the activation of the Mp by src, we used TAM67, a dominant negative mutant of c-Jun in which the transactivation domain has been deleted, leaving the DNA binding and the leucine zipper domain intact (54) . Our data in Figure 6 indicate that the activation of the human Mp by src is partially inhibited by TAM67, suggesting that AP-1 is a key downstream element recruited by src to form the AP-1 complex involved in Mp transactivation. We next investigated whether the inhibition of AP-1 transcriptional activity affects src-and HGF-induced cellular invasion. Therefore, TAM67 was stably introduced in MDCKts.src cells (Fig. 7A) . Functional analyses were performed on the TAM67-positive colonies (MDCKts.src-TAM67: pools 1 and 2 and clone 9), using the collagen invasion assay. As shown in Figure 7B , neutralization of the c-Jun pathway in MDCKts.src-TAM67 cells selectively abolished cellular invasion induced by the v-src oncogene at the permissive temperature, 35°C. Indeed, TAM67 had no effect on cellular invasion induced by HGF in MDCKts.src cells and did not reverse v-src protection from serum starvation-induced apoptosis in MDCKts.src cells incubated at 35°C (data not shown). Thus, the c-Jun/AP-1 motif is selectively involved in the signaling network initiated by src to control cellular invasion.
It is clear that the AP-1 response element is present in many protease genes implicated in cellular invasion, namely urokinase plasminogen activator, type I (MMP-1, -13) and type IV collagenases (MMP-9), stromelysin-1 (MMP-3), and matrilysin (27, (55) (56) (57) (58) (59) (60) (61) (62) . Previous studies also suggested that the MAPK activator Ki-ras induces the expression of matrilysin and AP-1 activation in SW1417 colon cancer cells (58) . On the other hand, src activity is overexpressed in the majority of human colonic tumors (23, 24) and correlates with elevated secretion of MMP-2 and expression of MMP-9 (25, 26) . The transformation of MDCK cells with v-src induces expression of membrane-type 1 matrix metalloproteases and invasiveness (63) . The AP-1 binding site is involved in the gelatinase-B (MMP-9) promoter activation by v-src in human fibrosarcoma cells (26) . Matrilysin was recently shown to induce cellular invasion via the cleavage of the adhesion/tumor suppressor E-cadherin ectodomain, a non-extracellular matrix substrate, providing the shedding of a derived E-cadherin proinvasive fragment in MDCKts.src cells (13) . Thus, the transforming functions of src and other oncogenes involved in colon cancer progression should be considered in view of a complex signaling network targeting AP-1 response elements in several matrix metalloprotease genes and other non-AP-1 transcriptional mechanisms controlled by src and targeting genes and signaling elements involved in cytoskeletal reorganization, cell motility, and tumor invasion.
Reversion of src-induced cellular invasion and endogenous matrilysin levels by the src tyrosine kinase inhibitor M475271
We have shown here that the src oncogene coordinates several cellular responses in kidney and colonic cancer cells, including activation of the matrilysin promoter, elevation of the matrilysin transcripts through the native promoter, c-Jun expression, and tumor cell invasiveness. To further investigate the potential impact of the src oncogenic pathway on the transfected Mp and matrilysin protein expression, we made use of the src tyrosine kinase inhibitor M475271 as an effective and selective drug acting against cellular invasion induced by src in MDCKts.src cells (Fig. 8A) . Indeed, invasion of collagen gels by MDCKts.src cells was abolished by M475271 in a concentration-dependent manner, with a potency IC 50 = 3x 10 −8 M. Under the same conditions, leptin-induced cellular invasion (64) was unaffected (data not shown). Total inhibition occurred at 10 −6 M M475271 (Fig. 8A) . Finally, we used the human colorectal cancer cell line HT-29 as a pertinent model to study the impact of the src tyrosine kinase inhibitor M475271 on MMP-7 protein levels (Fig. 8B) .
The HT-29 cell line displays an elevated src expression and activity that contribute to their tumorigenicity, as shown by a c-src-specific antisense strategy (23) . Most interestingly, a strong correlation was found between elevated c-src expression, kinase activity, and transcriptional activation of the SRC oncogene in a series of colonic cancer cell lines, including HT-29 (23) , suggesting that a self-activation loop is functional in high c-src expressing colorectal cancer cells. Activating SRC mutation at codon 531 was found in 12% of cases of advanced human colon cancer and was associated with cellular transformation and metastatic potential (24) . The unmasked SH3/SH2 domains in the activated src kinase conformation are also engaged in multiple intermolecular associations with upstream and downstream signaling elements involved in cellular adhesion, motility, proliferation, survival, and metastasis (65) . Increased c-src expression and/or kinase activity has also been reported in other solid tumors in breast, lung, pancreas and liver (66) (67) (68) (69) .
Because the active matrilysin protease is highly expressed in HT-29 cells (14), we next examined whether the inhibition of src activity by M475271 could affect endogenous matrilysin protein levels in HT-29 cells. Interestingly, we observed a remarkable time-and dose-dependent depletion of both inactive (28 kDa) and cleavage-activated (18 kDa) forms of matrilysin in the extracellular compartment of confluent HT-29 cells treated with the src tyrosine kinase inhibitor M475271 (Fig. 8B) , without affecting HT-29 cell survival (data not shown). Endogenous matrilysin levels (28 kDa band) were decreased by 60% in the conditioned medium prepared from HT-29 cells exposed for 24 h to 10 −6 M M475271 (Fig. 8B) . Similar results were obtained by Western blot analysis, using the src family chemical inhibitor PP1 (70) for 24 and 48 h reduced total matrilysin levels by 50% and 90%, respectively, measured by ELISA immunoassay.
Taken together, our data provide a molecular framework for understanding the complex relationship between src and its downstream pathways in the determination of the transformed and invasive phenotypes in human solid tumors. We identify the matrilysin gene as a transcriptional target of the src oncogenic pathway in kidney and colonic cancer cells. Oncogenic activation of src and matrilysin expression are early and frequent molecular defects implicated in the adenoma/adenocarcinoma conversion in the human colon (71) . We have identified a novel src-dependent transcriptional response, using two separate signaling pathways implicated in cellular invasion and metastasis, namely the PKC-p42/44 MAPK and the PI3-K cascades, converging to the AP-1 response element of the matrilysin promoter in premalignant and tumorigenic cancer cells. Alternatively, we have shown here that HCT8/S11 cells displaying an activated Wnt pathway demonstrate a nonconventional β-catenin-independent cooperation between LEF-1 and src to transactivate the Mp through the AP-1 motif, via a physical complex between the LEF-1 and c-Jun transcription factors. The stoichiometry and the sequential binding of these factors at the Mp delineate their synergistic cooperation on the Mp activity. Given the proximity of the AP-1 and Tcf binding site consensus sequences in the Mp and the ability of cJun and LEF-1 to interact with one other, we can presume that these factors can bind simultaneously to their adjacent response elements in src-transformed cells. The coactivator LEF-1 can also facilitate the assembly of the transcriptional machinery through interactions between distant DNA binding proteins by virtue of its own interaction domains with several transcription factors implicated in the coordination of developmental pathways (72) .
It is clear from our studies that inhibition of these two signaling pathways and transcriptional responses by pharmacological agents targeting the src tyrosine kinase and the AP-1 response element selectively abrogates src-induced cellular invasion. We thus provide a rationale for targeting the src/AP-1/LEF-1 signaling elements in order to control the metastatic potential of invasive cancer cells in primary tumors and distant target organs. This network could be a new target for the design of therapeutic strategies for the prevention and treatment of colorectal cancers, using oligo decoys (73) , silencing RNA strategies, and pharmacological inhibitors capable of down-regulating this src-dependent process at the Mp and other matrix protease genes controlled by the AP-1/LEF-1 transcription factors. 
